Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | BCKDK | O14874 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 6/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 5/20 | 0.43 |
| ▸ | PFKFB4 | Q16877 | 5/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226181 | 0.87 | NPSR1 (0.60) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| Hydrochloric Acid SCHEMBL6712744 | 0.86 | NPSR1 (0.59) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL788639 | 0.85 | NPSR1 (0.48) | NPSR1L3MBTL1MCL1BCKDKRXFP1 | |
| SCHEMBL5049535 | 0.85 | NPSR1 (0.48) | NPSR1L3MBTL1MCL1BCKDKRXFP1 | |
| SCHEMBL788508 | 0.76 | HSD11B1 (0.47) | L3MBTL1MCL1RXFP1CMA1PFKFB3 | |
| SCHEMBL3681719 | 0.75 | NPSR1 (0.36) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL3691284 | 0.74 | NPSR1 (0.36) | NPSR1L3MBTL1CMA1PFKFB3PFKFB4 | |
| SCHEMBL8285035 | 0.73 | MCL1 (0.44) | NPSR1L3MBTL1MCL1BCKDKRXFP1 | |
| SCHEMBL121901 | 0.72 | MCL1 (0.57) | MCL1BCKDKRXFP1NPC1RAB9A | |
| SCHEMBL12153769 | 0.72 | MCL1 (0.71) | NPSR1MCL1BCKDKRXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | NPSR1 1063/4885L3MBTL1 4149/4885MCL1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.